Leishmaniasis treatment: Macrophage scavenger receptor
利什曼病治疗:巨噬细胞清道夫受体
基本信息
- 批准号:7878000
- 负责人:
- 金额:$ 36.51万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-06-01 至 2012-12-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAmBisomeAmino AcidsAmphotericin BAmphotericin B LiposomalAntibioticsApolipoproteinsBindingCellsCharacteristicsChargeChemicalsChinese Hamster Ovary CellComplexConfocal MicroscopyCountryDendritic CellsDiseaseDoseDrug Delivery SystemsDrug FormulationsDrug KineticsDrug or chemical Tissue DistributionEngineeringFamilyGenetic EngineeringGoalsGrowthHepaticHumanImmune responseIn VitroInbred BALB C MiceIndividualInfectionKidneyKineticsLangerhans cellLeishmaniaLeishmania majorLeishmaniasisLesionLigandsLipidsLiposomesMeasuresMediatingMicellesMiltefosineModificationMolecularMonitorMouse StrainsMusMutationNatureParasitesParasitic DiseasesPeripheral Blood Mononuclear CellPharmaceutical PreparationsPhospholipidsPlasmaPolyenesPositioning AttributePreparationPropertyProteinsProtozoaRecombinantsResearchResearch PersonnelResistanceSR-A proteinsShapesSiteSite-Directed MutagenesisStructureT-LymphocyteTechnologyTestingTherapeutic IndexTissuesToxic effectTreatment ProtocolsVesicleamphotericin B-deoxycholatebasecell typecomparative efficacycytokinedesignin vivoinsightmacrophagemacrophage scavenger receptorsmembermouse modelnanoscalenovelparticlereceptorresearch studyresponsetargeted deliverytime interval
项目摘要
DESCRIPTION (provided by applicant): The long-term goal of our research is to apply the unique structural features and lipid interaction properties of apolipoproteins to the treatment of leishmaniasis. Apolipoproteins possess the capacity to transform phospholipid vesicles into discrete, nanometer scale, disc-shaped, complexes termed nanodisks (ND). Studies to date have shown that incorporation of specific hydrophobic drug molecules into ND is feasible. ND loaded with the polyene antibiotic amphotericin B (ampB) effectively inhibits fungal growth in vitro. Furthermore, in vivo experiments in Leishmania major infected mice have revealed that ampB-ND show efficacy at non-toxic doses. To investigate the molecular basis of this effect, pharmacokinetic studies will be performed to determine plasma decay kinetics and tissue distribution of ampB administered as ND. The apolipoprotein component of ND will be subject to chemical and/or genetic alteration to create a molecule that is recognized by the class A scavenger receptor (SR-A) on macrophages. Site-directed mutagenesis of the apolipoprotein component of ND will be performed to remove specific positively charged residues and position negatively charged amino acid residues such that they create a recognition site for SR-A. Chinese hamster ovary cells transfected with SR-A will be employed in binding experiments designed to measure the SR-A binding activity of engineered apolipoproteins. The efficacy of ampB-ND harboring apolipoprotein components targeted to SR-A will be evaluated in a mouse model of leishmaniasis. Studies will be performed to examine the potential enhancement achieved by incorporating ampB with a second hydrophobic anti-leishmanial drug, hexadecylphosphocholine, into ND. The extent to which ampB-ND induce parasite destruction in cells that harbor L. major will be assessed and the effect of ampB-ND exposure on the T cell/cytokine response of human peripheral blood mononuclear cells determined. The results of these experiments should offer new opportunity for the treatment of leishmaniasis, provide further insight into the ligand recognition characteristics of SR-A, and document the utility of ND as vehicles for targeted delivery of hydrophobic drugs.
描述(申请人提供):我们研究的长期目标是将载脂蛋白独特的结构特征和脂类相互作用特性应用于利什曼病的治疗。载脂蛋白具有将磷脂囊泡转化为离散的、纳米级的、圆盘状的复合体的能力,称为纳米盘(ND)。到目前为止的研究表明,将特定的疏水药物分子掺入ND是可行的。负载多烯抗生素两性霉素B(AmpB)的ND在体外能有效地抑制真菌生长。此外,在主要感染利什曼原虫的小鼠身上的体内实验表明,AmpB-ND在无毒剂量下显示出疗效。为了研究这种作用的分子基础,将进行药代动力学研究,以确定作为ND给药的AmpB的血浆衰减动力学和组织分布。ND的载脂蛋白成分将受到化学和/或遗传改变,以产生一种可由巨噬细胞上的A类清道夫受体(SR-A)识别的分子。将对ND的载脂蛋白成分进行定点突变,以去除特定的带正电荷的残基,并定位带负电荷的氨基酸残基,使它们为SR-A创建识别位点。转SR-A基因的中国仓鼠卵巢细胞将被用于检测工程载脂蛋白与SR-A结合活性的结合实验。含有针对SR-A的载脂蛋白成分的AmpB-ND将在利什曼病小鼠模型中进行疗效评估。将进行研究,以检验将AmpB与第二种疏水性抗利什曼药物十六烷基磷胆碱合并到ND中所实现的潜在增强。将评估AmpB-ND在携带主要乳杆菌的细胞中诱导寄生虫破坏的程度,并确定AmpB-ND暴露对人外周血单核细胞T细胞/细胞因子反应的影响。这些实验结果将为利什曼病的治疗提供新的机会,进一步深入了解SR-A的配体识别特性,并证明ND作为靶向递送疏水药物的载体的用途。
项目成果
期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nanodisks derived from amphotericin B lipid complex.
- DOI:10.1002/jps.21325
- 发表时间:2008-10
- 期刊:
- 影响因子:3.8
- 作者:Tufteland, Megan;Ren, Gang;Ryan, Robert O.
- 通讯作者:Ryan, Robert O.
Local suppression of T cell responses by arginase-induced L-arginine depletion in nonhealing leishmaniasis.
- DOI:10.1371/journal.pntd.0000480
- 发表时间:2009-07-14
- 期刊:
- 影响因子:3.8
- 作者:Modolell M;Choi BS;Ryan RO;Hancock M;Titus RG;Abebe T;Hailu A;Müller I;Rogers ME;Bangham CR;Munder M;Kropf P
- 通讯作者:Kropf P
Nanodisks protect amphotericin B from ultraviolet light and oxidation-induced damage.
纳米盘可保护两性霉素 B 免受紫外线和氧化引起的损伤。
- DOI:10.1002/ps.1712
- 发表时间:2009
- 期刊:
- 影响因子:4.1
- 作者:Tufteland,MeganL;Selitrennikoff,ClaudeP;ORyan,Robert
- 通讯作者:ORyan,Robert
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ROBERT O'Mara RYAN其他文献
ROBERT O'Mara RYAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ROBERT O'Mara RYAN', 18)}}的其他基金
2012 Lipoprotein Metabolism Gordon Research Conference and Gordon Research Semina
2012年脂蛋白代谢戈登研究会议暨戈登研究研讨会
- 批准号:
8318336 - 财政年份:2012
- 资助金额:
$ 36.51万 - 项目类别:
Leishmaniasis treatment: Macrophage scavenger receptor
利什曼病治疗:巨噬细胞清道夫受体
- 批准号:
7446196 - 财政年份:2006
- 资助金额:
$ 36.51万 - 项目类别:
Leishmaniasis treatment: Macrophage scavenger receptor
利什曼病治疗:巨噬细胞清道夫受体
- 批准号:
7631474 - 财政年份:2006
- 资助金额:
$ 36.51万 - 项目类别:
Leishmaniasis treatment: Macrophage scavenger receptor
利什曼病治疗:巨噬细胞清道夫受体
- 批准号:
7146804 - 财政年份:2006
- 资助金额:
$ 36.51万 - 项目类别:
Leishmaniasis treatment: Macrophage scavenger receptor
利什曼病治疗:巨噬细胞清道夫受体
- 批准号:
7235730 - 财政年份:2006
- 资助金额:
$ 36.51万 - 项目类别:
Apolipoprotein A-V: A Functional Proteomics Study
载脂蛋白 A-V:功能蛋白质组学研究
- 批准号:
7050130 - 财政年份:2004
- 资助金额:
$ 36.51万 - 项目类别:
Apolipoprotein A-V: A Functional Proteomics Study
载脂蛋白 A-V:功能蛋白质组学研究
- 批准号:
7216401 - 财政年份:2004
- 资助金额:
$ 36.51万 - 项目类别:
Apolipoprotein A-V: A Functional Proteomics Study
载脂蛋白 A-V:功能蛋白质组学研究
- 批准号:
6774551 - 财政年份:2004
- 资助金额:
$ 36.51万 - 项目类别:
Apolipoprotein A-V: A Functional Proteomics Study
载脂蛋白 A-V:功能蛋白质组学研究
- 批准号:
7905068 - 财政年份:2004
- 资助金额:
$ 36.51万 - 项目类别:
相似海外基金
High Dose AMBISOME on a Fluconazole Backbone for Cryptococcal Meningitis Induction Therapy in sub-Saharan Africa: A Randomized Controlled Trial
高剂量 AMBISOME 以氟康唑为骨架,用于撒哈拉以南非洲地区隐球菌性脑膜炎的诱导治疗:一项随机对照试验
- 批准号:
MC_PC_MR/P006922/1 - 财政年份:2016
- 资助金额:
$ 36.51万 - 项目类别:
Research Grant
150 603:TRIAL OF VORICONAZOLE VS AMBISOME FOR ANTIFUNGAL THERAPY IN H
150 603:伏立康唑与安比索姆在 H 中的抗真菌治疗试验
- 批准号:
6309596 - 财政年份:1999
- 资助金额:
$ 36.51万 - 项目类别:
150 603:TRIAL OF VORICONAZOLE VS AMBISOME FOR ANTIFUNGAL THERAPY IN H
150 603:伏立康唑与安比索姆在 H 中的抗真菌治疗试验
- 批准号:
6265806 - 财政年份:1999
- 资助金额:
$ 36.51万 - 项目类别:
AMBISOME VS APHOTERICIN B IN AIDS PATIENTS WITH CRYPTOCOCCAL MENINGITIS
Ambisome 与 APHOTERICIN B 治疗隐球菌性脑膜炎艾滋病患者的疗效
- 批准号:
6115716 - 财政年份:1998
- 资助金额:
$ 36.51万 - 项目类别:
AMBISOME VS AMPHOTERICIN B FOLLOWED BY FLUCONAZOLE IN TREATMENT OF MENINGITIS
Ambisome 对比两性霉素 B 并随后使用氟康唑治疗脑膜炎
- 批准号:
6117822 - 财政年份:1998
- 资助金额:
$ 36.51万 - 项目类别:
AMBISOME COMPARED WITH AMPHOTERICIN B FOR HISTOPLASMOSIS IN AIDS PTS
Ambisome 与两性霉素 B 治疗艾滋病患者组织胞浆菌病的比较
- 批准号:
6121106 - 财政年份:1998
- 资助金额:
$ 36.51万 - 项目类别:
AMBISOME VS AMPHOTERICIN B AND FLUCONAZOLE IN CRYPTOCOCCAL MENINGITIS IN AIDS
Ambisome 对比两性霉素 B 和氟康唑治疗艾滋病隐球菌性脑膜炎
- 批准号:
6121097 - 财政年份:1998
- 资助金额:
$ 36.51万 - 项目类别:
AMBISOME VS AMPHOTERICIN B FOLLOWED BY FLUCONAZOLE IN TREATMENT OF MENINGITIS
Ambisome 对比两性霉素 B 并随后使用氟康唑治疗脑膜炎
- 批准号:
6291052 - 财政年份:1998
- 资助金额:
$ 36.51万 - 项目类别:
AMBISOME WITH CONVENTIONAL AMPHOTERICIN B FOR INDUCTION THERAPY OF HISTOPLASMOSIS
Ambisome 与传统两性霉素 B 联合用于组织胞浆菌病的诱导治疗
- 批准号:
6291058 - 财政年份:1998
- 资助金额:
$ 36.51万 - 项目类别:
AMBISOME WITH CONVENTIONAL AMPHOTERICIN B FOR INDUCTION THERAPY OF HISTOPLASMOSIS
Ambisome 与传统两性霉素 B 联合用于组织胞浆菌病的诱导治疗
- 批准号:
6117820 - 财政年份:1998
- 资助金额:
$ 36.51万 - 项目类别:














{{item.name}}会员




